Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 244

Posts Tagged ‘jefferies’

Jefferies Agrees to Sell Remaining 31% Interest in National Beef to Marfrig

Posted by fidest press agency su mercoledì, 20 novembre 2019

Jefferies Financial Group Inc. (NYSE:JEF) (“Jefferies”) announced today that it has entered into a definitive agreement to sell its remaining 31% interest in National Beef to Marfrig Global Foods (“Marfrig”). This follows our original sale to Marfrig of a 48% interest in National Beef in June 2018. Under the terms of this agreement, Jefferies will realize a total of $970 million in cash, including $860 million of proceeds from Marfrig and $110 million from final distributions from National Beef. Closing is expected on or about November 30, 2019, subject to limited and customary closing conditions. The transaction will result in a pre-tax gain of approximately $210 million being recognized by Jefferies. Our last published valuation of our remaining interest in National Beef was $903 million as of May 31, 2019. Since that date, we have received $66 million in distributions and now a further $970 million for our remaining interest.Rich Handler, CEO, and Brian Friedman, President, of Jefferies, commented: “We have sold our interest in National Beef at what we consider an attractive price and in furtherance of our stated strategic goals of focusing and investing in Investment Banking, Capital Markets and Asset Management, simplifying our overall company, reducing volatility and lumpiness in our results, and returning excess capital to shareholders.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

The Jefferies London Healthcare Conference

Posted by fidest press agency su giovedì, 14 novembre 2019

London. CONMED Corporation (NASDAQ: CNMD) today announced that Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the Jefferies London Healthcare Conference at 9:20 a.m. GMT (4:20 a.m. ET) on Wednesday, November 20, 2019 in London, UK.A live webcast of the presentation will be accessible through the “Investors” section of the Company’s website at http://www.conmed.com and will be available for replay following the event. CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery, thoracic surgery and gastroenterology. For more information, visit http://www.conmed.com.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Jefferies Appoints Fred Jallot Head of Fixed Income in Europe

Posted by fidest press agency su mercoledì, 21 novembre 2018

Jefferies today announced the appointment of Fred Jallot as Head of Fixed Income, Europe. He will be based in the firm’s London office starting January 2, 2019 and will report to Fred Orlan, Global Head of Fixed Income at Jefferies. Tim Cronin, who has also served as Head of Fixed Income, Europe, will relinquish this role and continue to serve as President of Jefferies International Limited, Jefferies’ London-based subsidiary.“We are very excited to have Fred Jallot join Jefferies’ leading global fixed income platform,” commented Mr. Orlan. “As a broadly experienced professional in global fixed income, his relationships and leadership will further enhance Jefferies’ growth in this market. This senior hire is an example of Jefferies’ emphasis on enhancing our firm’s European capabilities to serve our regional and global client base,” he added.Mr. Jallot was most recently Global Head of Credit and Asset-Backed Securities in Europe, the Middle East and Africa at Nomura, and previously spent 12 years at Citigroup and five years at Deutsche Bank.Jefferies Group LLC, the largest independent full-service global investment banking firm focused on serving clients for over 55 years, is a leader in providing insight, expertise and execution to investors, companies and governments. Our firm provides a full range of investment banking, advisory, sales and trading, research and wealth management services across all products in the Americas, Europe and Asia. Jefferies Group LLC is a wholly-owned subsidiary of Jefferies Financial Group Inc. (NYSE: JEF), a diversified financial services company.

Posted in Estero/world news, Uncategorized | Contrassegnato da tag: , , | Leave a Comment »

FLX Bio to Present at the Jefferies Global Healthcare Conference

Posted by fidest press agency su domenica, 3 giugno 2018

FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of oral small-molecule drugs to activate the immune system, today announced that Brian Wong, M.D., Ph.D., President and CEO will present at the Jefferies Global Healthcare Conference on June 8, 2018 at 8:00a.m. ET in New York. A live webcast and audio archive of the presentation may be accessed here or on the FLX Bio website at https://www.flxbio.com/newsroom. Please connect to the website 10 minutes prior to the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. FLX Bio, Inc. is an immuno-oncology company focused on the discovery and development of orally-available, small molecule drugs to activate the immune system and eradicate cancer. Using its integrated immuno-oncology drug discovery platform, FLX Bio’s small molecule compounds specifically target proteins and pathways important for regulatory T cells or myeloid cells within the tumor microenvironment. Its lead candidate FLX475, a best-in-class CCR4 inhibitor, entered Phase 1 studies in December 2017 and has the potential to be used alone or in combination with checkpoint inhibitors to treat a variety of cancers. The company employs a precision medicine strategy for prospective patient selection in clinical studies, applying its robust computational and translational biology capabilities to identify key biomarkers that should maximize clinical response and increase the probability of clinical success. In addition, FLX is developing small molecule inhibitors of GCN2, a stress response kinase that detects amino acid starvation in the tumor microenvironment, and USP7, a therapeutic target involved in multiple cancer pathways.Located in South San Francisco, Calif., and funded by leading investors, including The Column Group (TCG), Kleiner Perkins (KP), Topspin Partners, GV (formerly Google Ventures) and Celgene Corporation, FLX Bio has assembled a leadership team and advisory group with a proven track record of success and team of scientists with substantial knowledge and expertise in drug discovery and translational areas essential to execute on this approach. http://www.flxbio.com.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »